e-learning
resources
Munich 2006
Monday 04.09.2006
Biology and prognostic factors
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Targeting gene of insulin-like growth factor type I (IGF-I) on
in vitro
model of A549 cell line with triple-helix approach. Perspectives of gene therapy in non-small cell lung (NSCLC) cancer
P. Kopinski, J. Tujakowski, K. Bartczak, J. Golinska, A. Szpechcinski, P. Jarocki (Bydgoszcz, Krakow, Poland)
Source:
Annual Congress 2006 - Biology and prognostic factors
Session:
Biology and prognostic factors
Session type:
Poster Discussion
Number:
2296
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Kopinski, J. Tujakowski, K. Bartczak, J. Golinska, A. Szpechcinski, P. Jarocki (Bydgoszcz, Krakow, Poland). Targeting gene of insulin-like growth factor type I (IGF-I) on
in vitro
model of A549 cell line with triple-helix approach. Perspectives of gene therapy in non-small cell lung (NSCLC) cancer. Eur Respir J 2006; 28: Suppl. 50, 2296
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Optimizing invasive ventilation for SMA type 1 children who are receiving the gene therapy
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
Related content which might interest you:
Specific plasmids encoding shRNA molecules directed against growth factor receptors in cell proliferation inhibition and induction phenotype changes relevant to enhancement of anti-tumor immunity. Model of human non-small (NSCLC) and small (SCLC) cell lung cancer lines
Source: Annual Congress 2010 - Pathology of lung cancer
Year: 2010
Inhibition of insulin-like growth factor type I (IGF-I) gene in A549 human lung cancer cell line enhances cell apoptosis and causes phenotype changes relevant to increased tumor susceptibility to immune system
Source: Eur Respir J 2007; 30: Suppl. 51, 715s
Year: 2007
Bevacizumab (Avastin®) aerosol therapy (AT) inhibits primary and metastatic tumor growth in a murine model with human non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Increased vascular-endothelial growth factor a (VEGF-A) expression and response to angiogenesis inhibitor erlotinib in non-small-cell lung cancer (NSCLC) – hint for a new predictive marker?
Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology
Year: 2007
Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer
Source: Eur Respir J 2011; 37: 183-193
Year: 2011
Efficacy of Afatinib, Erlotinib, and Gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis: a network meta-analysis
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018
A blood-based test for epidermal growth factor receptor mutations in patients with non-small cell lung cancer
Source: Annual Congress 2008 - Therapy in thoracic oncology
Year: 2008
Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung cancer and its correlation with survival
Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer
Year: 2009
The prognostic value of serum epidermal growth factor receptor (EGFR) levels in patients with non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 674s
Year: 2004
The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer
Source: Eur Respir Rev 2010 19: 186-196
Year: 2010
Nationwide real-world cohort study of first line TKI treatment in epidermal growth factor receptor mutated non-small cell lung cancer.
Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Year: 2020
Epidermal growth factor receptor (EGFR) expression in non-small cell lung carcinoma (NSCLC) and survival
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
A prospective phase II study of gefitinib for chemo-naïve patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations
Source: Annual Congress 2006 - Lung cancer treatment
Year: 2006
Epidermal growth factor receptor mutation status in advanced non-small cell lung cancer: A single institution experience
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012
Epithelial growth factor receptor (EGFR) mutation status and the treatment of non-small cell lung cancer (NSCLC): A population based quality assurance analysis
Source: International Congress 2015 – Quality management in lung cancer
Year: 2015
Clinical features associated with epidermal growth factor receptor and K-RAS gene mutations in non-small cell lung cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 811s
Year: 2006
Expression of vascular endothelial growth factor (VEGF) and association with lymphangiogenesis in non small cell (NSCLC) and small cell lung carcinomas (SCLC)
Source: Eur Respir J 2006; 28: Suppl. 50, 386s
Year: 2006
Inhibition of the effect of epidermal growth factor (EGF) on lung cancer cells. The use of plasmids encoding specific siRNA molecules
Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer
Year: 2015
Phenotype pattern of human non-small cell lung cancer (NSCLC) model line in immune escape phenomenon. Effect of transfection with plasmids encoding specific anti-EGFR1 and anti-HER2/neu short hairpin (SH)RNA sequences
Source: Annual Congress 2009 - Basic science and lung cancer
Year: 2009
Expression of tumor necrosis factor receptor 2 in human non-small cell lung cancer and its role as a potential prognostic biomarker
Source: International Congress 2019 – Biology of lung cancer
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept